Trials / Completed
CompletedNCT00095069
Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Groups Efficacy and Safety Extension Study of MK0928 in the Treatment of Adult Outpatients With Primary Insomnia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (planned)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to study the safety and effectiveness of MK0928 for adults with insomnia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0928, gaboxadol / Duration of Treatment - 1 year | |
| DRUG | Comparator: placebo / Duration of Treatment -1 year |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2007-02-01
- Completion
- 2007-02-01
- First posted
- 2004-11-01
- Last updated
- 2015-01-14
Source: ClinicalTrials.gov record NCT00095069. Inclusion in this directory is not an endorsement.